Publication | Closed Access

Dosimetry and dose–response relationships in newly diagnosed patients with malignant gliomas treated with Iodine-131-Labeled anti-tenascin monoclonal antibody 81C6 therapy

Neuro-oncologyOncologyRadiation TherapyGliomaDose–response RelationshipsPharmacotherapyCancer TreatmentMedicineRadiation OncologyNuclear MedicineMalignant Gliomas